Potential integration of therapies under development High risk individuals (Prophylactic treatment) Healthcare providers Vaccine for (Prophylactic treatment) population Patient infected with SARS-CoV-2 Severity of illness Immune Plasma- Viral modulation derived Rx Symptom inhibition treatment Immunity Mild / Moderate Moderate / Severe symptoms symptoms Serology testing IQVIA Global Executive Briefing: COVID-19 June 2020; Copyright 2020 IQVIA. 12